IL17A and rheumatoid arthritis: Ixekizumab (LY2439821), a humanized IgG4 anti-IL17A mAb has showed efficacy in phases I and II in RA [44] and psoriasis [45], respectively, and is currently being studied in RA, PsA and psoriasis.